berberine has been researched along with Depression in 14 studies
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of behavioral tests demonstrated that berberine attenuated the depression-like behaviors induced by CORT." | 8.31 | Berberine ameliorates depression-like behaviors in mice via inhibiting NLRP3 inflammasome-mediated neuroinflammation and preventing neuroplasticity disruption. ( Cheng, D; Li, W; Qin, Z; Shi, DD; Tsoi, B; Wang, Z; Zhang, S; Zhang, YD; Zhang, ZJ; Zhao, J, 2023) |
| "The CUMS model and behavioral evaluation were utilized in this study to evaluate the efficacy of berberine in the treatment of depression." | 8.31 | Berberine attenuates depression-like behavior by modulating the hippocampal NLRP3 ubiquitination signaling pathway through Trim65. ( Chen, F; Huang, Y; Liu, W; Su, K; Tao, W; Wang, Y; Yang, L; Zhao, M, 2023) |
| "Proteomic analysis of reserpine-induced depression and the effects of berberine on this were investigated to delineate the possible underlying mechanism." | 8.12 | Label-free quantitative proteomic analysis of reserpine-induced depression in mice intervened by berberine. ( Wang, Y; Yang, N; Zou, L, 2022) |
| "A high-performance liquid chromatography-tandem mass spectrometry(LC-MS/MS) was developed for simultaneously determining the components(magnoflorine, jatrorrhizine, berberrubine, coptisine, berberine) of Jiaotai Pills and Fluoxetine in plasma of rats with chronic unpredictable mild stress(CUMS)-induced depression to investigate the pharmacokinetic herb-drug interaction of Jiaotai Pills and Fluoxetine in the rats." | 8.12 | [Pharmacokinetic interaction of Jiaotai Pills and Fluoxetine in rats with CUMS-induced depression]. ( Cao, Y; Chen, SS; Dai, GL; Ju, WZ; Li, FR; Li, Y; Liu, MC; Wang, YQ; Yang, XY, 2022) |
| "Berberine, which is a potential antidepressant, exhibits definite efficiency in modulating the gut microbiota." | 5.91 | Berberine ameliorates depression-like behavior in CUMS mice by activating TPH1 and inhibiting IDO1-associated with tryptophan metabolism. ( Ge, PY; Guo, R; Ni, SJ; Qi, YY; Qu, SY; Yang, NY; Yao, ZY; Zhang, QC; Zhao, X; Zhu, HX, 2023) |
| "Chronic stress and depression are challenging conditions to treat, owing to their complexity and lack of clinically available and effective therapeutic agents." | 5.46 | Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays. ( Liu, H; Sun, Y; Zhang, C; Zhu, X, 2017) |
| "The CUMS model and behavioral evaluation were utilized in this study to evaluate the efficacy of berberine in the treatment of depression." | 4.31 | Berberine attenuates depression-like behavior by modulating the hippocampal NLRP3 ubiquitination signaling pathway through Trim65. ( Chen, F; Huang, Y; Liu, W; Su, K; Tao, W; Wang, Y; Yang, L; Zhao, M, 2023) |
| "A high-performance liquid chromatography-tandem mass spectrometry(LC-MS/MS) was developed for simultaneously determining the components(magnoflorine, jatrorrhizine, berberrubine, coptisine, berberine) of Jiaotai Pills and Fluoxetine in plasma of rats with chronic unpredictable mild stress(CUMS)-induced depression to investigate the pharmacokinetic herb-drug interaction of Jiaotai Pills and Fluoxetine in the rats." | 4.12 | [Pharmacokinetic interaction of Jiaotai Pills and Fluoxetine in rats with CUMS-induced depression]. ( Cao, Y; Chen, SS; Dai, GL; Ju, WZ; Li, FR; Li, Y; Liu, MC; Wang, YQ; Yang, XY, 2022) |
| "Chronic corticosterone (CORT) stress is an anxiety and depression inducing factor that involves the dysfunction of glucocorticoid receptor (GR), brain-derived neurotrophic factor (BDNF), and neuronal plasticity." | 3.91 | Proteomic profiling of the neurons in mice with depressive-like behavior induced by corticosterone and the regulation of berberine: pivotal sites of oxidative phosphorylation. ( Du, LJ; Feng, YL; Gao, HW; Gong, Q; He, LL; Lei, F; Li, J; Luo, YY; Wang, ML; Yan, XJ; Yang, SL, 2019) |
| "More studies are still warranted in similar rodent models of pain and depression, so, that the present findings can be further substantiated to establish the clinical effectiveness of berberine in a subset of patients suffering from pain as well as depression." | 3.79 | Possible involvement of oxido-nitrosative stress induced neuro-inflammatory cascade and monoaminergic pathway: underpinning the correlation between nociceptive and depressive behaviour in a rodent model. ( Arora, V; Chopra, K, 2013) |
| "Berberine, which is a potential antidepressant, exhibits definite efficiency in modulating the gut microbiota." | 1.91 | Berberine ameliorates depression-like behavior in CUMS mice by activating TPH1 and inhibiting IDO1-associated with tryptophan metabolism. ( Ge, PY; Guo, R; Ni, SJ; Qi, YY; Qu, SY; Yang, NY; Yao, ZY; Zhang, QC; Zhao, X; Zhu, HX, 2023) |
| "BACKGROUND Depression is the 5th most prevalent disorder adversely affecting the health of humans worldwide." | 1.56 | Ginkgolide-Platinum(II) Complex GPt(II) Exhibits Therapeutic Effect on Depression in Mice via Upregulation of DA and 5-HT Neurotransmitters. ( Chen, H; Liu, L; Wang, N; Wang, X; Yang, T, 2020) |
| "Chronic stress and depression are challenging conditions to treat, owing to their complexity and lack of clinically available and effective therapeutic agents." | 1.46 | Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays. ( Liu, H; Sun, Y; Zhang, C; Zhu, X, 2017) |
| "Treatment with berberine prevented these changes above." | 1.43 | Berberine up-regulates the BDNF expression in hippocampus and attenuates corticosterone-induced depressive-like behavior in mice. ( Fang, XY; Hu, CY; Jin, SL; Li, YC; Ma, LG; Pei, YY; Shen, JD, 2016) |
| "Berberine at lower dose did not affect the locomotor activity and barbiturate-induced sleep time." | 1.35 | On the mechanism of antidepressant-like action of berberine chloride. ( Dhir, A; Kulkarni, SK, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 9 (64.29) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, N | 1 |
| Zou, L | 1 |
| Wang, Y | 3 |
| Ge, PY | 1 |
| Qu, SY | 1 |
| Ni, SJ | 1 |
| Yao, ZY | 1 |
| Qi, YY | 1 |
| Zhao, X | 1 |
| Guo, R | 1 |
| Yang, NY | 1 |
| Zhang, QC | 1 |
| Zhu, HX | 1 |
| Yang, XY | 1 |
| Dai, GL | 1 |
| Chen, SS | 1 |
| Li, Y | 1 |
| Liu, MC | 1 |
| Li, FR | 1 |
| Cao, Y | 1 |
| Wang, YQ | 1 |
| Ju, WZ | 1 |
| Huang, M | 1 |
| He, Y | 1 |
| Tian, L | 1 |
| Yu, L | 1 |
| Cheng, Q | 1 |
| Li, Z | 1 |
| Gao, L | 1 |
| Gao, S | 1 |
| Yu, C | 1 |
| Qin, Z | 1 |
| Shi, DD | 1 |
| Li, W | 1 |
| Cheng, D | 1 |
| Zhang, YD | 1 |
| Zhang, S | 1 |
| Tsoi, B | 1 |
| Zhao, J | 1 |
| Wang, Z | 1 |
| Zhang, ZJ | 1 |
| Yang, L | 1 |
| Huang, Y | 1 |
| Chen, F | 1 |
| Su, K | 1 |
| Zhao, M | 1 |
| Tao, W | 1 |
| Liu, W | 1 |
| Gong, Q | 1 |
| Yan, XJ | 1 |
| Lei, F | 1 |
| Wang, ML | 1 |
| He, LL | 1 |
| Luo, YY | 1 |
| Gao, HW | 1 |
| Feng, YL | 1 |
| Yang, SL | 1 |
| Li, J | 1 |
| Du, LJ | 1 |
| Wang, QS | 1 |
| Li, K | 1 |
| Gao, LN | 1 |
| Zhang, Y | 1 |
| Lin, KM | 1 |
| Cui, YL | 1 |
| Yang, T | 1 |
| Wang, X | 1 |
| Liu, L | 1 |
| Chen, H | 1 |
| Wang, N | 1 |
| Zhang, JH | 1 |
| Yang, HZ | 1 |
| Su, H | 1 |
| Song, J | 1 |
| Bai, Y | 1 |
| Deng, L | 1 |
| Feng, CP | 1 |
| Guo, HX | 1 |
| Gao, X | 1 |
| Gu, Y | 1 |
| Zhen, Z | 1 |
| Lu, Y | 1 |
| Zhu, X | 1 |
| Sun, Y | 1 |
| Zhang, C | 1 |
| Liu, H | 1 |
| Arora, V | 1 |
| Chopra, K | 1 |
| Shen, JD | 1 |
| Ma, LG | 1 |
| Hu, CY | 1 |
| Pei, YY | 1 |
| Jin, SL | 1 |
| Fang, XY | 1 |
| Li, YC | 1 |
| Kulkarni, SK | 1 |
| Dhir, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders[NCT02983188] | Phase 2/Phase 3 | 113 participants (Actual) | Interventional | 2018-04-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 other studies available for berberine and Depression
| Article | Year |
|---|---|
Label-free quantitative proteomic analysis of reserpine-induced depression in mice intervened by berberine.
Topics: Animals; Antipsychotic Agents; Berberine; Depression; Male; Mice; Mice, Inbred ICR; Proteomics; Rese | 2022 |
Berberine ameliorates depression-like behavior in CUMS mice by activating TPH1 and inhibiting IDO1-associated with tryptophan metabolism.
Topics: Animals; Berberine; Chromatography, Liquid; Depression; Disease Models, Animal; Indoleamine-Pyrrole | 2023 |
[Pharmacokinetic interaction of Jiaotai Pills and Fluoxetine in rats with CUMS-induced depression].
Topics: Animals; Berberine; Chromatography, Liquid; Depression; Drugs, Chinese Herbal; Fluoxetine; Rats; Tan | 2022 |
Gut microbiota-SCFAs-brain axis associated with the antidepressant activity of berberine in CUMS rats.
Topics: Animals; Antidepressive Agents; Berberine; Brain-Derived Neurotrophic Factor; Depression; Disease Mo | 2023 |
Berberine ameliorates depression-like behaviors in mice via inhibiting NLRP3 inflammasome-mediated neuroinflammation and preventing neuroplasticity disruption.
Topics: Animals; Berberine; Depression; Inflammasomes; Male; Mice; Mice, Inbred C57BL; Neuroinflammatory Dis | 2023 |
Berberine attenuates depression-like behavior by modulating the hippocampal NLRP3 ubiquitination signaling pathway through Trim65.
Topics: Animals; Berberine; Depression; Hippocampus; Inflammasomes; Inflammation; Interleukin-18; Mice; NLR | 2023 |
Proteomic profiling of the neurons in mice with depressive-like behavior induced by corticosterone and the regulation of berberine: pivotal sites of oxidative phosphorylation.
Topics: Animals; Behavior, Animal; Berberine; Cell Survival; Corticosterone; Depression; Disease Models, Ani | 2019 |
Intranasal delivery of berberine via in situ thermoresponsive hydrogels with non-invasive therapy exhibits better antidepressant-like effects.
Topics: Administration, Intranasal; Animals; Antidepressive Agents; Berberine; Blood-Brain Barrier; Depressi | 2020 |
Ginkgolide-Platinum(II) Complex GPt(II) Exhibits Therapeutic Effect on Depression in Mice via Upregulation of DA and 5-HT Neurotransmitters.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Berberine; Depression; Disease Models, Animal; Dop | 2020 |
Berberine and Ginsenoside Rb1 Ameliorate Depression-Like Behavior in Diabetic Rats.
Topics: Animals; Berberine; Blood Glucose; Depression; Diabetes Mellitus, Experimental; Diet, High-Fat; Drug | 2021 |
Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays.
Topics: Animals; Behavior, Animal; Berberine; Bifidobacterium; Body Weight; Depression; Disease Models, Anim | 2017 |
Possible involvement of oxido-nitrosative stress induced neuro-inflammatory cascade and monoaminergic pathway: underpinning the correlation between nociceptive and depressive behaviour in a rodent model.
Topics: Animals; Berberine; Caspase 3; Cerebral Cortex; Depression; Disease Models, Animal; Dopamine; Hippoc | 2013 |
Berberine up-regulates the BDNF expression in hippocampus and attenuates corticosterone-induced depressive-like behavior in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Berberine; Brain-Derived Neurotrophic Factor; Cort | 2016 |
On the mechanism of antidepressant-like action of berberine chloride.
Topics: Analgesics; Animals; Antidepressive Agents; Behavior, Animal; Berberine; Body Temperature; Brain; De | 2008 |